Department for Internal Medicine II, University Medical Center Regensburg, 93053 Regensburg, Germany.
Institute of Physiology, University of Regensburg, 93053 Regensburg, Germany.
Int J Mol Sci. 2023 Sep 17;24(18):14198. doi: 10.3390/ijms241814198.
Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular events and sudden cardiac death. Although arrhythmias are one of the most common causes of sudden cardiac death in CKD patients, the molecular mechanisms involved in the development of arrhythmias are still poorly understood. In this narrative review, therefore, we summarize the current knowledge on the regulation of cardiac ion channels that contribute to arrhythmia in CKD. We do this by first explaining the excitation-contraction coupling, outlining current translational research approaches, then explaining the main characteristics in CKD patients, such as abnormalities in electrolytes and pH, activation of the autonomic nervous system, and the renin-angiotensin-aldosterone system, as well as current evidence for proarrhythmic properties of uremic toxins. Finally, we discuss the substance class of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on their potential to modify cardiac channel regulation in CKD and, therefore, as a treatment option for arrhythmias.
慢性肾脏病(CKD)与心血管事件和心源性猝死的风险显著增加相关。尽管心律失常是 CKD 患者心源性猝死的最常见原因之一,但涉及心律失常发生的分子机制仍知之甚少。因此,在这篇叙述性综述中,我们总结了目前关于调节心脏离子通道的知识,这些离子通道有助于 CKD 中的心律失常。我们首先解释兴奋-收缩偶联,概述当前的转化研究方法,然后解释 CKD 患者的主要特征,如电解质和 pH 值异常、自主神经系统激活以及肾素-血管紧张素-醛固酮系统,以及尿毒症毒素的致心律失常特性的现有证据。最后,我们讨论了钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)的物质类别,它们有可能改变 CKD 中心脏通道的调节,因此作为心律失常的治疗选择。